SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix's upcoming earnings are sparking active debate, especially after the stock traded down in the after-hours session. While revenue was in line with estimates, EPS missed, and some community members are attributing the dip to a tax dispute in Brazil and broader concerns about content. A potential stock split and the impact of increased competition and advertising revenue are also key talking points.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a proposed private offering of convertible senior notes, leading to community discussion about dilution and its impact on long-term holders; some view this as a strategic move to secure funding before positive catalysts, while others express concern about the company's financial management and potential for further offerings; the community is also debating the recent analyst downgrade and its effect on the stock's trajectory.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to its acquisition of Railbird, a prediction market platform, sparking discussions about the company's expansion into new markets beyond sports betting. While some express excitement about this growth and potential, others are skeptical, citing concerns about profitability and regulatory challenges, with community members closely watching how this move impacts the stock's value.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

ISRG is trending due to strong earnings and raised guidance, sparking debate about its valuation and future growth potential. While some community members celebrate the positive report and anticipate further gains, others express concerns about margin pressures and potential saturation in the US market. Bullish sentiment highlights the company's leadership in robotic surgery and potential for international expansion.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending due to an earnings report that beat expectations but was followed by a weaker-than-expected forecast, sparking concerns about cautious commentary and potential impacts from trade tensions. The community is actively discussing whether the stock is overvalued and anticipating a significant price movement, with some expecting a bounce while others foresee further declines. Some traders believe analysts are paid to pump before ER as a tactic for unloading stock.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amidst speculation of a potential acquisition, with Paramount Skydance reportedly interested in making a bid, although the deal's likelihood is debated. Community chatter revolves around potential offer prices and whether WBD will accept, with some anticipating a bidding war involving other major players like Netflix or Comcast. The stock's movement reflects investor uncertainty surrounding these ongoing acquisition rumors and what price a deal could actually happen at.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending due to a massive surge following news of a $200M financing deal aimed at advancing its schizophrenia treatment. Community chatter revolves around the potential for significant gains, while some traders caution about a possible pump and dump, leading to high volatility. The funding is viewed as a strong indicator of confidence in the drug's approval, sparking debates about its long-term potential versus short-term trading opportunities.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as investors analyze recent analyst ratings, upcoming catalysts related to their CML and obesity programs, and a strong cash position lasting into 2028. Unusual options activity and insider buying have also caught the attention of traders, though some express concern over lack of recent news and data. Community members are actively discussing potential buyout scenarios and comparing TERN's prospects to others in the GLP-1 space.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences a significant pullback, prompting community discussion about potential bottom levels and future catalysts. Despite the recent downturn, some investors express confidence in the company's long-term prospects, citing a major deal with Microsoft and overall growth in the AI sector. Community members are actively debating whether to buy the dip or wait for further price declines.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending as investors discuss NAV erosion and debate the merits of its high-yield, covered call strategy amid market volatility. Concerns about the fund's management and the impact of share dilution on its price are also circulating within the community. Despite some expressing frustration, others remain committed, focusing on the potential for long-term income through weekly dividend payouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments

Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...

BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR  (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?

Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

BeOne Medicines Ltd. - Sponsored ADR  (ONC) Surges 4.0%: Is This an Indication of Further Gains?

BeOne Medicines Ltd. - Sponsored ADR  (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven by encouraging results from a late-stage cancer drug trial.The company’s sponsor, Akeso, announced that a phase 3 trial evaluating Summit’s drug, ivonescimab, in combination with chemotherapy, met its primary endpoint of progression-free survival in patients with advanced squamous non-small cell lung cancer (NSCLC).Akeso conducted the study across multiple centers in China, comparing the combination against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.An independent data monitoring committee found that the ivonescimab arm demonstrated statistically significant and clinically meaningful improvement.Summit plans to present the full dataset from the trial at a major medical conference later this year.&nbsp;On Stocktwits, sentiment for Summit rose further within 'extremely bullish' levels amid a 507% spike in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SMMT_sentiment_and_message_volume_as_of_April_23_png_a70ccf1959.webp" alt="SMMT sentiment and message volume as of April 23.png" width="1318" height="316"><figcaption>SMMT sentiment and message volume as of April 23. | source: Stocktwits</figcaption></figure>One bullish watcher urged investors to watch out for a "short squeeze up to $40."<stembedurl>https://stocktwits.com/BooEmmy/message/612403946</stembedurl>"The path is rising. And the journey has only just begun," said another.<stembedurl>https://stocktwits.com/Teluride/message/612467520</stembedurl>Summit is enrolling patients in a separate multiregional study pitting the same combination against pembrolizumab (Merck's Keytruda) plus chemo in first-line metastatic NSCLC. Early trial results from China have already shown promising results.The company also boosted investor enthusiasm after joining a clinical trial&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/smmt-retail-chatter-explodes-on-pfizer-trial-pact/chdEqVTRx8">collaboration</a> with Pfizer in February.Summit's stock has surged by over 84% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Equity

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.


BeiGene to Present at Upcoming Investor Conferences

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...

<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio shares</a> surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks&nbsp;while lifting retail sentiment.The clinical-stage immunotherapy company announced a collaboration and supply agreement with BeiGene to conduct a confirmatory Phase 3 clinical trial.&nbsp;The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for patients with advanced or metastatic non-small cell lung cancer who have developed resistance to immune checkpoint inhibitor therapy.According to ImmunityBio, multiple Phase 1 and 2 studies have already shown prolonged overall survival with this combination compared to historical chemotherapy results in similar patients.&nbsp;The upcoming Phase 3 trial, conducted globally across multiple sites, will enroll 462 participants. The primary endpoint is overall survival, while secondary measures include disease control rate, progression-free survival, objective response rate, and safety.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IBRX_sentiment_and_message_volume_Jan_29_015db24b68.png" alt="IBRX sentiment and message volume Jan 29.png" width="1318" height="324"><figcaption>IBRX sentiment and message volume Jan 29 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘bullish’ for ImmunityBio on Wednesday, up from ‘neutral’ a day ago, while BeiGene’s sentiment shifted to ‘extremely bullish’ amid a spike in message volume.&nbsp;One user speculated that BeiGene could also become ImmunityBio’s global partner for bladder cancer treatments, suggesting another announcement might follow soon.&nbsp;<stembedurl>https://stocktwits.com/Dmck9/message/601987411</stembedurl>Another post predicted a 150% rally in the coming weeks.<stembedurl>https://stocktwits.com/Terrashae/message/601984996</stembedurl>ImmunityBio has been a closely watched stock among retail traders, with its Stocktwits following growing by nearly 43% in the past year despite a 10% decline in the stock’s price over the same period.&nbsp;Year to date, however, shares are up nearly 28%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

BeOne Medicines Ltd - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

ONC
BeiGene Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ONC News

ONCBeiGene Ltd - ADR